- Home
- WEA vs RENB Comparison
WEA vs RENB Comparison
Compare WEA & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- RENB
- Stock Information
- Founded
- WEA 2002
- RENB 2011
- Country
- WEA United States
- RENB United States
- Employees
- WEA N/A
- RENB N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- WEA Finance
- RENB Health Care
- Exchange
- WEA Nasdaq
- RENB Nasdaq
- Market Cap
- WEA 131.1M
- RENB 121.3M
- IPO Year
- WEA N/A
- RENB N/A
- Fundamental
- Price
- WEA $11.06
- RENB $0.76
- Analyst Decision
- WEA
- RENB
- Analyst Count
- WEA 0
- RENB 0
- Target Price
- WEA N/A
- RENB N/A
- AVG Volume (30 Days)
- WEA 46.1K
- RENB 1.8M
- Earning Date
- WEA 01-01-0001
- RENB 02-12-2025
- Dividend Yield
- WEA 7.87%
- RENB N/A
- EPS Growth
- WEA N/A
- RENB N/A
- EPS
- WEA N/A
- RENB N/A
- Revenue
- WEA N/A
- RENB N/A
- Revenue This Year
- WEA N/A
- RENB N/A
- Revenue Next Year
- WEA N/A
- RENB N/A
- P/E Ratio
- WEA N/A
- RENB N/A
- Revenue Growth
- WEA N/A
- RENB N/A
- 52 Week Low
- WEA $9.60
- RENB $0.40
- 52 Week High
- WEA $11.29
- RENB $5.25
- Technical
- Relative Strength Index (RSI)
- WEA 55.83
- RENB 41.96
- Support Level
- WEA $10.59
- RENB $0.70
- Resistance Level
- WEA $11.14
- RENB $0.94
- Average True Range (ATR)
- WEA 0.17
- RENB 0.12
- MACD
- WEA 0.05
- RENB -0.03
- Stochastic Oscillator
- WEA 73.64
- RENB 11.03
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.